Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma. (Q39324107)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

title

Effector memory and central memory NY-ESO-1-specific re-directed T cells for treatment of multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

Sarah R Haile

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

author name string

P C Schuberth

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

G Jakka

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

A Wadle

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

F Gautschi

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

D Haley

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

A Mischo

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

G Held

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

M Thiel

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

M Tinguely

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

C B Bifulco

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

B A Fox

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

C Renner

14

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

U Petrausch

15

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

publication date

28 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

386-395

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22739387%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Management of older patients with multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Recent major improvement in long-term survival of younger patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

NY-ESO-1 immunotherapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Molecules and mechanisms of the graft-versus-leukaemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Immunotherapy of cancer through targeting of minor histocompatibility antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

NY-ESO-1: review of an immunogenic tumor antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Dissecting cytotoxic T cell responses towards the NY-ESO-1 protein by peptide/MHC-specific antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Rational development of high-affinity T-cell receptor-like antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Supernatural T cells: genetic modification of T cells for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Polychromatic flow cytometry: a rapid method for the reduction and analysis of complex multiparameter data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Adoptive T cell therapy for cancer in the clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Central memory and effector memory T cell subsets: function, generation, and maintenance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Failing immune control as a result of impaired CD8+ T-cell maturation: CD27 might provide a clue

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Lineage relationship and protective immunity of memory CD8 T cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

The precursors of memory: models and controversies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

CD8+ T-cell memory in tumor immunology and immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Phenotype and functional characterization of long-term gp100-specific memory CD8+ T cells in disease-free melanoma patients before and after boosting immunization

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Chimeric NKG2D receptor-expressing T cells as an immunotherapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Ex vivo culture of chimeric antigen receptor T cells generates functional CD8+ T cells with effector and central memory-like phenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Generation of effector CD8+ T cells and their conversion to memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Generation of CD19-chimeric antigen receptor modified CD8+ T cells derived from virus-specific central memory T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Cancer-testis antigens are commonly expressed in multiple myeloma and induce systemic immunity following allogeneic stem cell transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Establishment of a new model of human multiple myeloma using NOD/SCID/gammac(null) (NOG) mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

DNA-dependent kinase (p350) as a candidate gene for the murine SCID defect

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

inferred from DOI database lookup

7 January 2021

based on heuristic

Proliferation and differentiation potential of human CD8+ memory T-cell subsets in response to antigen or homeostatic cytokines

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48

inferred from DOI database lookup

7 January 2021

based on heuristic

Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays

1 reference

https://api.crossref.org/works/10.1038%2FGT.2012.48